Cargando…

Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells

Lenalidomide is an immunomodulatory drug with therapeutic activity in chronic lymphocytic leukemia (CLL). However, it has pleiotropic effects, and the mechanism of action responsible for its therapeutic activity has not been well defined yet. Herein, we show that lenalidomide treatment does not have...

Descripción completa

Detalles Bibliográficos
Autores principales:	Acebes-Huerta, Andrea, Huergo-Zapico, Leticia, Gonzalez-Rodriguez, Ana Pilar, Fernandez-Guizan, Azahara, Payer, Angel R., López-Soto, Alejandro, Gonzalez, Segundo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4182694/ https://www.ncbi.nlm.nih.gov/pubmed/25313353 http://dx.doi.org/10.1155/2014/265840

Ejemplares similares

Lenalidomide and Chronic Lymphocytic Leukemia
por: González-Rodríguez, Ana Pilar, et al.
Publicado: (2013)

Expansion of NK Cells and Reduction of NKG2D Expression in Chronic Lymphocytic Leukemia. Correlation with Progressive Disease
por: Huergo-Zapico, Leticia, et al.
Publicado: (2014)

Pleiotropic Anti-Angiogenic and Anti-Oncogenic Activities of the Novel Mithralog Demycarosyl-3D-ß-D-Digitoxosyl-Mithramycin SK (EC-8042)
por: Fernández-Guizán, Azahara, et al.
Publicado: (2015)

Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia
por: Villa-Álvarez, Mónica, et al.
Publicado: (2018)

Regulation of NKG2D signaling during the epithelial-to-mesenchymal transition
por: López-Soto, Alejandro, et al.
Publicado: (2013)

Molecular Bases for the Regulation of NKG2D Ligands in Cancer
por: Huergo-Zapico, Leticia, et al.
Publicado: (2014)

BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2021)

BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2023)

NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?
por: Cantoni, Claudia, et al.
Publicado: (2016)

Mechanisms of Apoptosis Resistance to NK Cell-Mediated Cytotoxicity in Cancer
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2020)

LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2021)

Driver Mutations and Single Copy Number Abnormalities Identify Binet Stage A Patients with Chronic Lymphocytic Leukemia with Aggressive Progression
por: Gonzalez-Rodriguez, Ana P., et al.
Publicado: (2020)

Lenalidomide in the Treatment of Chronic Lymphocytic Leukemia
por: Cortelezzi, Agostino, et al.
Publicado: (2012)

The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling
por: Lorenzo-Herrero, Seila, et al.
Publicado: (2019)

Immunomodulation of NK Cells by Ionizing Radiation
por: Chen, Jiarui, et al.
Publicado: (2020)

Mechanisms of Resistance to NK Cell Immunotherapy
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2020)

NK Cell-Based Immunotherapy in Cancer Metastasis
por: Lorenzo-Herrero, Seila, et al.
Publicado: (2018)

Unravelling soluble immune checkpoints in chronic lymphocytic leukemia: Physiological immunomodulators or immune dysfunction
por: Landeira-Viñuela, Alicia, et al.
Publicado: (2022)

Antitumor effect of lenalidomide in malignant glioma cell lines
por: Hanashima, Yuya, et al.
Publicado: (2020)

NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications
por: Sportoletti, Paolo, et al.
Publicado: (2021)

Effect of Lenalidomide Maintenance in Chronic Lymphocytic Leukemia: A Meta-Analysis and Trial-Sequential Analysis
por: Yu, Tsung-Ying, et al.
Publicado: (2022)

PB1873: EFFECTS OF LENALIDOMIDE MAINTENANCE IN CHRONIC LYMPHOCYTIC LEUKEMIA: A TRIAL-SEQUENTIAL ANALYSIS
por: Lee, C.-H., et al.
Publicado: (2022)

AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma
por: Ailawadhi, Sikander, et al.
Publicado: (2023)

Immunomodulating and Antitumor Activities of Panellus serotinus Polysaccharides
por: Kim, Jeong Hwa, et al.
Publicado: (2012)

Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies
por: McDaniel, Jessica M., et al.
Publicado: (2012)

Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia
por: Hofland, Tom, et al.
Publicado: (2019)

Sarcoma IL-12 overexpression facilitates NK cell immunomodulation
por: Rademacher, Mary Jo, et al.
Publicado: (2021)

Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells
por: Otáhal, Pavel, et al.
Publicado: (2015)

NK Cells in the Treatment of Hematological Malignancies
por: Gonzalez-Rodriguez, Ana P, et al.
Publicado: (2019)

The Emerging Role of NK Cells in Immune Checkpoint Blockade
por: Martinez-Perez, Alejandra, et al.
Publicado: (2022)

Fibroblasts Impair Migration and Antitumor Activity of NK-92 Lymphocytes in a Melanoma-on-Chip Model
por: Iaia, Ilenia, et al.
Publicado: (2022)

Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia
por: Wang, Zong-Han, et al.
Publicado: (2023)

Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy
por: Desai, Madhav, et al.
Publicado: (2013)

The Antitumor Potential of λ-Carrageenan Oligosaccharides on Gastric Carcinoma by Immunomodulation
por: Tang, Min, et al.
Publicado: (2023)

Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints
por: Winqvist, Maria, et al.
Publicado: (2016)

The CXCR4–STAT3–IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide
por: Shaim, Hila, et al.
Publicado: (2018)

Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial
por: Pettitt, Andrew R., et al.
Publicado: (2020)

Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial
por: Schroeder, Thomas, et al.
Publicado: (2023)

Antitumor and immunomodulating activities of six Phellinus igniarius polysaccharides of different origins
por: Gao, Wenwen, et al.
Publicado: (2017)

The Effect of Cucurbit[7]uril on the Antitumor and Immunomodulating Properties of Oxaliplatin and Carboplatin
por: Pashkina, Ekaterina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tab7a4578re280s3nsh6fulc91